These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 35211861)
1. Cytoreductive Surgery with HIPEC is a Safe and Effective Palliative Option in Chemorefractory Symptomatic Peritoneal Metastasis. Zhang C; Patel A; Hegeholz D; Brown K; Shostrom V; Pottebaum M; Foster JM Ann Surg Oncol; 2022 May; 29(5):3337-3346. PubMed ID: 35211861 [TBL] [Abstract][Full Text] [Related]
2. Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still beneficial in patients diagnosed with colorectal peritoneal metastasis who underwent palliative chemotherapy? Cho HJ; Kim JW; Kim WR Asian J Surg; 2024 Jan; 47(1):296-302. PubMed ID: 37648541 [TBL] [Abstract][Full Text] [Related]
3. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy]. Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167 [No Abstract] [Full Text] [Related]
4. Palliative Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Is It Safe and Effective? Strong EA; Livingston A; Gracz M; Peltier W; Tsai S; Christians K; Gamblin TC; Kersting K; Clarke CN J Surg Res; 2022 Oct; 278():31-38. PubMed ID: 35588572 [TBL] [Abstract][Full Text] [Related]
5. Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience. Valenzuela CD; Levine EA; Mangieri CW; Gawdi R; Moaven O; Russell G; Lundy ME; Perry KC; Votanopoulos KI; Shen P Ann Surg Oncol; 2022 Jun; 29(6):3436-3445. PubMed ID: 35286531 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy. Zhou S; Jiang Y; Liang J; Pei W; Zhou Z World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125 [TBL] [Abstract][Full Text] [Related]
7. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis. Hajjar R; Mercier F; Passot G; Pasquer A; Gelli M; Levine EA; Villeneuve L; Poncet G; Walter T; Glehen O Eur J Surg Oncol; 2022 Jul; 48(7):1626-1630. PubMed ID: 35418324 [TBL] [Abstract][Full Text] [Related]
8. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis. Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149 [TBL] [Abstract][Full Text] [Related]
9. Perioperative and Oncological Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis of Rectal Origin. Benvenisti H; Shiber M; Assaf D; Shovman Y; Laks S; Elbaz N; Mor E; Zippel D; Nissan A; Ben-Yaacov A; Adileh M J Gastrointest Surg; 2023 Nov; 27(11):2506-2514. PubMed ID: 37726508 [TBL] [Abstract][Full Text] [Related]
10. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients. Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213 [TBL] [Abstract][Full Text] [Related]
11. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis. van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584 [TBL] [Abstract][Full Text] [Related]
12. Outcomes of Stable Lung Colorectal Metastases on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Pantelis A; Ben-Yaacov A; Adileh M; Schtrechman G; Shacham-Shmueli E; Boursi B; Margalit O; Halpern N; Mor E; Assaf D; Maximiliano K; Nissan A; Laks S J Gastrointest Surg; 2022 Aug; 26(8):1724-1731. PubMed ID: 35768716 [TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus R0 resection for resectable colorectal cancer with peritoneal metastases and low peritoneal cancer index scores: a collaborative observational study from Korea and Japan. Kitaguchi D; Park EJ; Baik SH; Sasaki S; Tsukada Y; Ito M Int J Surg; 2024 Jan; 110(1):45-52. PubMed ID: 37800569 [TBL] [Abstract][Full Text] [Related]
14. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis. Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884 [TBL] [Abstract][Full Text] [Related]
15. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with improved perioperative outcomes: a single-center early experience propensity-matched analysis. Shaltiel T; Solomon D; Pletcher ER; Golas BJ; Magge DR; Sarpel U; Labow DM; Cohen NA Surg Endosc; 2022 Aug; 36(8):6153-6161. PubMed ID: 35080674 [TBL] [Abstract][Full Text] [Related]
16. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450 [TBL] [Abstract][Full Text] [Related]
17. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies. Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880 [TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups. Gomes David M; Bakrin N; Salleron J; Kaminsky MC; Bereder JM; Tuech JJ; Lehmann K; Mehta S; Glehen O; Marchal F BMC Surg; 2022 Jan; 22(1):1. PubMed ID: 34996419 [TBL] [Abstract][Full Text] [Related]
19. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis]. Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170 [No Abstract] [Full Text] [Related]
20. Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases. Steinhoff H; Acs M; Blaj S; Dank M; Herold M; Herold Z; Herzberg J; Sanchez-Velazquez P; Strate T; Szasz AM; Piso P World J Gastroenterol; 2023 May; 29(18):2850-2863. PubMed ID: 37274066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]